CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Co-Diagnostics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.67+0.01 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $2.87M
- P/E (TTM)
- –
- Dividend yield
- –
Co-Diagnostics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Market Cap | $4.16M | $230.55M |
| Enterprise Value | $514.41K | $202.97M |
| PS Ratio | 5.77 | 3.10 |
| PB Ratio | 0.33 | 3.04 |
| P/TBV Ratio | 0.76 | 4.43 |
Enterprise value
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| EV / Sales | 0.71 | 2.91 |
Income (trailing twelve months)
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Revenue | $721.39K | $102.39M |
| Gross Profit | $313.64K | $60.36M |
| Operating Income | -$48.96M | -$4.31M |
| Pretax Income | -$48.68M | -$2.37M |
| Net Income | -$47.06M | -$6.57M |
| EBITDA | -$47.97M | -$1.98M |
| EPS (Diluted) | -$23.99 | -$0.08 |
Margins
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Gross Margin | 43.5% | 55.2% |
| Operating Margin | -6787.6% | -6.04% |
| Pretax Margin | -6747.7% | -4.11% |
| Profit Margin | -6523.0% | -10.5% |
| EBITDA Margin | -6650.1% | -2.67% |
| FCF Margin | -3808.0% | 0.02% |
Returns
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -176.2% | -18.2% |
| Return on Assets (ROA) | -149.3% | -13.3% |
| Return on Invested Capital (ROIC) | -212.5% | -3.69% |
| Return on Capital Employed (ROCE) | -356.7% | -9.07% |
Growth
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -28.1% | 8.85% |
| Revenue Growth (3Y CAGR) | -73.7% | 7.08% |
| Revenue Growth (5Y CAGR) | -61.6% | 11.8% |
Balance sheet
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.65M | $36.66M |
| Net Cash (Debt) | $3.65M | $3.92M |
| Net Cash Per Share | $0.58 | $0.28 |
| Equity (Book Value) | $12.71M | $55.33M |
| Book Value Per Share | $2.03 | $2.87 |
| Tangible Book Value | $5.49M | $10.79M |
| Working Capital | $2.33M | $56.72M |
Financial position
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Current Ratio | 1.81 | 2.48 |
| Quick Ratio | 1.29 | 1.53 |
Cash flow (trailing twelve months)
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Operating Cash Flow | -$27.10M | -$566.22K |
| Capital Expenditures | -$367.37K | -$3.69M |
| Free Cash Flow | -$27.47M | -$696.00K |
| FCF Per Share | -$4.39 | -$0.02 |
Efficiency
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | 0.58 |
| Inventory Turnover | 0.42 | 2.21 |
| Revenue Per Employee | $6.27K | $322.92K |
| Profits Per Employee | -$409.19K | -$51.88K |
| Employee Count | 115 | 185 |
Dividends and yields
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Earnings Yield | -1130.1% | -6.88% |
| FCF Yield | -659.7% | -0.45% |
Shares
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Shares Outstanding | 6,252,320 | 44,302,700 |
| Shares Change (YoY) | 130.2% | 3.36% |
| Shares Change (QoQ) | 35.4% | 0.27% |
| Float | 5,333,840 | 37,462,700 |
| Shares Held by Insiders | 14.7% | 10.5% |
| Shares Held by Institutions | 9.53% | 63.5% |
Taxes
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Income Tax | -$1.62M | $1.52M |
Scores
| Measure | Co-Diagnostics | Industry median |
|---|---|---|
| Altman Z-Score | -16.97 | 1.95 |
| Piotroski F-Score | 1 | 5 |
| Beneish M-Score | 0.30 | -2.64 |
Calculated by StockData from Co-Diagnostics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.